Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBI-031 in Diabetic Macular Edema
NCT02842541Phase 1Withdrawn
- Sponsor
- Sesen Bio
- Start
- Sep 2016
- Primary completion
- Oct 2017
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of vamikibart in diabetic macular edema (DME) (2 arms), sponsored by Sesen Bio. Primary endpoints: Adverse Events at 84 days, Anti-Drug Antibodies at 84 days and 1 more. Planned start Sep 2016; status: withdrawn.
02
Drugs
vamikibart
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02842541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02842541.